Carisma Therapeutics (CARM) said Sunday that new preclinical data showed the potential of the company's engineered macrophages in multiple liver fibrosis models.
Results of the study showed that the engineered macrophages significantly reduced liver fibrosis and hepatic stellate cell activation. The engineered macrophages were also well tolerated in the study, the company said.
The company anticipates to nominate a development candidate for its liver fibrosis program in Q1 2025.
Price: 1.0407, Change: -0.01, Percent Change: -0.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。